News & Updates

Use of the cholesterol 24-hydroxylase inhibitor soticlestat as adjunctive therapy in patients with Lennox–Gastaut syndrome (LGS) falls short of reducing the frequency of major motor drop (MMD) seizures, according to the results of the phase III SKYWAY trial.

Nintedanib is the only antifibrotic approved in Hong Kong for progressive pulmonary fibrosis and systemic sclerosis–associated interstitial lung disease (ILD). Read further on how nintedanib slows lung function decline in connective tissue disease–associated ILD (CTD-ILD), as well as ERS/EULAR 2025 guideline recommendations on screening, diagnosis, monitoring, and treatment of CTD-ILD.

The 2026 ASA Practice Guideline provides strong recommendations with moderate-strength evidence for FPBs as essential components of perioperative pain management across open cardiothoracic, abdominal, retroperitoneal, pelvic surgeries, mastectomy, and minimally invasive abdominal procedures.

The use of once-daily, low-dose prednisolone for glucocorticoid replacement in adrenal insufficiency yields substantial improvements in bone turnover and cardiometabolic health markers compared with multiple-dose hydrocortisone, according to the results of a crossover randomized clinical trial.

Systemic lupus erythematosus (SLE) patients with acute coronary syndrome (ACS) need a longer hospital stay and accrue higher charges, resulting in higher healthcare utilization, reports a study.

In patients with deficiency of adenosine deaminase 2 (DADA2) vasculitis, early age of onset and periodic illness are associated with disease-related damage, but prompt initiation of a tumour necrosis factor inhibitor (TNFi) may prevent complications and severe progression, suggests a study.

Biomarker testing where appropriate and novel tailored combination therapies targeting multiple pathways simultaneously may address the high unmet need and optimize treatment outcomes in hormone receptor–positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (mBC) patients who develop resistance or have disease recurrence while on endocrine-based therapy (ET), said Professor Sherko Kümmel of the Interdisciplinary Breast Unit Clinics, Essen-Mitte, Germany, who spoke at the 14^th Asia-Pacific Breast Cancer Summit (APBCS 2026).

Treatment with LEVI-04—a p75 neurotrophin receptor (p75NTR) fusion protein that inhibits neurotrophin-3—helps improve pain and function in patients with knee osteoarthritis, as shown in a phase II trial.